| IKZF1/3 and CRL4CRBN E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma S Barrio, U Munawar, YX Zhu, N Giesen, CX Shi, M Da Viá, R Sanchez, ... Haematologica 105 (5), e237, 2020 | 69 | 2020 |
| CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF‐MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous … MC Da Vià, AG Solimando, A Garitano‐Trojaola, S Barrio, U Munawar, ... The oncologist 25 (2), 112-118, 2020 | 50 | 2020 |
| Cereblon enhancer methylation and IMiD resistance in multiple myeloma L Haertle, S Barrio, U Munawar, S Han, X Zhou, C Vogt, RA Fernández, ... Blood, The Journal of the American Society of Hematology 138 (18), 1721-1726, 2021 | 41 | 2021 |
| Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis AM Poos, N Prokoph, MJ Przybilla, JP Mallm, S Steiger, I Seufert, L John, ... Blood 142 (19), 1633-1646, 2023 | 22 | 2023 |
| Assessment of TP53 lesions for p53 system functionality and drug resistance in multiple myeloma using an isogenic cell line model U Munawar, M Roth, S Barrio, H Wajant, D Siegmund, RC Bargou, ... Scientific Reports 9 (1), 18062, 2019 | 22 | 2019 |
| Hierarchy of mono- and biallelic TP53 alterations in multiple myeloma cell fitness U Munawar, L Rasche, N Müller, C Vogt, M Da-Via, L Haertle, ... Blood, The Journal of the American Society of Hematology 134 (10), 836-840, 2019 | 12 | 2019 |
| Single-nucleotide variants and epimutations induce proteasome inhibitor resistance in multiple myeloma L Haertle, S Barrio, U Munawar, S Han, X Zhou, M Simicek, C Vogt, ... Clinical Cancer Research 29 (1), 279-288, 2023 | 11 | 2023 |
| Adhesion-mediated multiple myeloma (MM) disease progression: Junctional adhesion molecule a enhances angiogenesis and multiple myeloma dissemination and predicts poor survival AG Solimando, MC Da Via, P Leone, G Croci, P Borrelli, PT Gaviria, ... Blood 134, 855, 2019 | 10 | 2019 |
| Melflufen efficacy in multiple myeloma with TP53 aberrations A Slipicevic, U Munawar, T Stühmer, J Aschan, F Lehmann, ... Cancer Research 80 (16_Supplement), 1843-1843, 2020 | 8 | 2020 |
| Mechanisms of proteasome inhibitor resistance selected by clonal evolution in multiple myeloma L Haertle, S Barrio, M Simicek, U Munawar, R Sanchez, M Bittrich, ... Blood 134, 4349, 2019 | 7 | 2019 |
| High-dose carfilzomib achieves superior anti-tumor activity over low-dose and recaptures response in relapsed/refractory multiple myeloma resistant to low-dose carfilzomib by … X Zhou, A Besse, J Peter, MJ Steinhardt, C Vogt, S Nerreter, E Teufel, ... Haematologica 108 (6), 1628, 2023 | 5 | 2023 |
| Genetic alterations in members of the proteasome 26S subunit, AAA-ATPase (PSMC) gene family in the light of proteasome inhibitor resistance in multiple myeloma L Haertle, N Buenache, HN Cuesta Hernández, M Simicek, R Snaurova, ... Cancers 15 (2), 532, 2023 | 5 | 2023 |
| Advanced risk stratification in multiple myeloma beyond traditional FISH: the first prospective real-world evidence for SKY92 gene expression profiling X Zhou, A Hofmann, C Vogt, S Nerreter, E Teufel, E Stanojkovska, ... Blood 140 (Supplement 1), 4273-4274, 2022 | 5 | 2022 |
| Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myeloma U Munawar, J Theuersbacher, MJ Steinhardt, X Zhou, S Han, S Nerreter, ... Haematologica 109 (11), 3670, 2024 | 3 | 2024 |
| Characterization of mercury-resistant rhizobacteria for plant growth promotion: An in vitro and in silico approach A Amin, M Naveed, U Munawar, A Sarwar, Z Latif Current Microbiology 78, 3968-3979, 2021 | 3 | 2021 |
| Focusing PI and IMiD resistance in multiple myeloma: Impact of DNA methylation L Haertle, M Bittrich, R Potabattula, MC Da Via, U Munawar, ... Blood 132, 404, 2018 | 3 | 2018 |
| Functional Characterization of GPRC5D alteration and Its Impact on Talquetamab Resistance in Relapsed/Refractory Multiple Myeloma S Han, U Munawar, L Haertle, C Vogt, S Nerreter, E Teufel, X Zhou, ... Blood 142 (Supplement 1), 3323-3323, 2023 | 2 | 2023 |
| Secondary genetic events impact the expression of key immunotargets on the surface of multiple myeloma cells U Munawar, P Eiring, C Vogt, L Haertle, S Han, S Nerreter, E Teufel, ... Blood 142 (Supplement 1), 451-451, 2023 | 2 | 2023 |
| Immune Checkpoint CD200/CD200R Decreases T Cell-Mediated Cytotoxicity Via Dok2 and Is Regulated By P53 in Multiple Myeloma P Shah, T Stuehmer, L Haertle, D Bruennert, U Munawar, E Leich, ... Blood 140 (Supplement 1), 7076-7077, 2022 | 2 | 2022 |
| Implications of TP53 alterations for therapy response in multiple myeloma U Munawar, S Barrio, M Roth, H Einsele, RC Bargou, T Stuehmer, ... Blood 132 (Supplement 1), 3189-3189, 2018 | 2 | 2018 |
